ATE483972T1 - Reagenzien und verfahren für krebsprognose und pathologische einstufung - Google Patents

Reagenzien und verfahren für krebsprognose und pathologische einstufung

Info

Publication number
ATE483972T1
ATE483972T1 AT07757161T AT07757161T ATE483972T1 AT E483972 T1 ATE483972 T1 AT E483972T1 AT 07757161 T AT07757161 T AT 07757161T AT 07757161 T AT07757161 T AT 07757161T AT E483972 T1 ATE483972 T1 AT E483972T1
Authority
AT
Austria
Prior art keywords
reagents
methods
cancer prognosis
pathological grading
grading
Prior art date
Application number
AT07757161T
Other languages
English (en)
Inventor
Gary Pestano
Linda Samadzadeh
Original Assignee
Ventana Med Syst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Med Syst Inc filed Critical Ventana Med Syst Inc
Application granted granted Critical
Publication of ATE483972T1 publication Critical patent/ATE483972T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07757161T 2006-02-16 2007-02-16 Reagenzien und verfahren für krebsprognose und pathologische einstufung ATE483972T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77456306P 2006-02-16 2006-02-16
PCT/US2007/062362 WO2007095644A2 (en) 2006-02-16 2007-02-16 Reagents and methods for cancer prognosis and pathological staging

Publications (1)

Publication Number Publication Date
ATE483972T1 true ATE483972T1 (de) 2010-10-15

Family

ID=38335516

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07757161T ATE483972T1 (de) 2006-02-16 2007-02-16 Reagenzien und verfahren für krebsprognose und pathologische einstufung

Country Status (10)

Country Link
US (2) US20070207489A1 (de)
EP (2) EP1984735B1 (de)
JP (1) JP5143026B2 (de)
CN (2) CN101384901A (de)
AT (1) ATE483972T1 (de)
AU (1) AU2007214427B2 (de)
CA (1) CA2642542C (de)
DE (1) DE602007009645D1 (de)
ES (1) ES2354181T3 (de)
WO (1) WO2007095644A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007137187A2 (en) 2006-05-18 2007-11-29 Molecular Profiling Institute, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
WO2010017822A1 (en) 2008-08-15 2010-02-18 Visiopharm A/S A method and a system for determining a target in a biological sample by image analysis
US9697582B2 (en) 2006-11-16 2017-07-04 Visiopharm A/S Methods for obtaining and analyzing images
EP2156370B1 (de) 2007-05-14 2011-10-12 Historx, Inc. Abteilungsauftrennung durch pixelcharakterisierung unter verwendung von bilddatenclusterung
EP2162728B1 (de) 2007-06-15 2016-07-27 Novartis AG Mikroskopisches system und verfahren zur erfassung von standardisierten daten
CA2604317C (en) 2007-08-06 2017-02-28 Historx, Inc. Methods and system for validating sample images for quantitative immunoassays
CA2596204C (en) 2007-08-07 2019-02-26 Historx, Inc. Method and system for determining an optimal dilution of a reagent
WO2009029810A1 (en) 2007-08-31 2009-03-05 Historx, Inc. Automatic exposure time selection for imaging tissue
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
WO2010033508A1 (en) 2008-09-16 2010-03-25 Historx, Inc. Reproducible quantification of biomarker expression
CA2743211A1 (en) 2008-11-12 2010-05-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods and systems of using exosomes for determining phenotypes
US20120003664A1 (en) * 2008-12-09 2012-01-05 Uffe Lovborg Method for evaluating pre-treatment
WO2010083252A2 (en) 2009-01-14 2010-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ratio based biomarkers and methods of use thereof
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
CN102939538A (zh) * 2010-05-07 2013-02-20 霍夫曼-拉罗奇有限公司 用于离体检测细胞的诊断方法
CN101876659B (zh) * 2010-06-29 2013-02-13 同济大学 用于检测肿瘤的量子点试剂盒
RU2565550C2 (ru) 2010-09-24 2015-10-20 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Прямой захват, амплификация и секвенирование днк-мишени с использованием иммобилизированных праймеров
US9410207B2 (en) * 2011-12-30 2016-08-09 Abbott Molecular Inc. Method and compositions for detecting epidermal growth factor receptor variant forms in cancer cells
JP6619339B2 (ja) * 2013-08-30 2019-12-11 ソシエテ・デ・プロデュイ・ネスレ・エス・アー ポリープ再発
BR112016017132B1 (pt) * 2014-01-28 2024-01-30 Quest Diagnostics Investments Incorporated Métodos para identificar uma zona de célula tipo tronco de câncer, uma zona de transição de adenoma-adenocarcinoma, um tumor de cólon, células-tronco de câncer, um indivíduo com câncer colorretal provável de responder favoravelmente ao tratamento com uma terapia alvejada pela via nf-kb, um indivíduo com perda genômica de 18q/smad4 e de 10q/pten, para diagnosticar um indivíduo com alto grau de adenoma de cólon e adenocarcinoma inicial, e para determinar a probabilidade de um tumor de cólon em um indivíduo passar por uma transformação invasiva se deixado sem tratamento e a probabilidade de um indivíduo com câncer colorretal (crc) responder favoravelmente ao tratamento com uma terapia alvejada pela via tgf-beta, e, kit para identificar uma região de transição de (...).
CN103882139B (zh) * 2014-04-04 2015-06-03 上海赛安生物医药科技有限公司 一种用于化疗方案选择的多重基因检测试剂盒
EP3249401B1 (de) * 2015-01-22 2019-12-25 Konica Minolta, Inc. Quantifizierungsverfahren für biologische substanz, pathologisches diagnoseunterstützungssystem und programm
US10517823B1 (en) * 2016-08-10 2019-12-31 Verily Life Sciences Llc ROS—responsive liposomes for specific targeting
CN107688092B (zh) * 2017-08-18 2020-05-19 国家纳米科学中心 一种用于癌症患者预后评估的方法
EP3761031A4 (de) 2018-02-28 2022-06-01 Nitto Boseki Co., Ltd. Verfahren zur isolierung von zellkernen mit erhöhter antigenizität aus immobilisierten zellen oder ffpe-gewebeabschnitten sowie antigenaktivator und kit dafür

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4741900A (en) * 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US6872817B1 (en) 1986-01-16 2005-03-29 The Regents Of The Univ. Of California Method of staining target interphase chromosomal DNA
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US6326148B1 (en) * 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
WO2001092338A1 (en) * 2000-06-01 2001-12-06 The Brigham And Women's Hospital, Inc. Diagnosis of endometrial precancers
EP1360496A4 (de) * 2001-02-16 2005-03-09 Immunivest Corp Verfahren und reagenzien zur schnellen und effizienten isolierung zirkulierender krebszellen
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
WO2004000102A2 (en) * 2002-06-19 2003-12-31 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
ES2400339T3 (es) * 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
WO2004044218A2 (en) * 2002-11-05 2004-05-27 The Regents Of The University Of California Methods and materials for examining pathways associated with glioblastoma progression
CA2527321A1 (en) * 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
DE10345021A1 (de) * 2003-09-23 2005-05-04 Univ Potsdam Verfahren zur nichtinvasiven Früherkennung von Dickdarmkrebs und/oder Darmkrebsvorläuferzellen
EP1774044A4 (de) * 2004-06-03 2009-06-10 Univ Johns Hopkins Verfahren zur überprüfung von zellproliferation oder neoplastischer störungen
EP3042964A1 (de) * 2004-06-04 2016-07-13 Genentech, Inc. Egfr-mutationen
CA2583389A1 (en) * 2004-10-07 2006-04-20 Emory University Multifunctional nanoparticles conjugates and their use
EP2473495A1 (de) * 2009-09-18 2012-07-11 Almac Discovery Limited Pharmazeutische verbindungen

Also Published As

Publication number Publication date
EP2290361A1 (de) 2011-03-02
CA2642542A1 (en) 2007-08-23
WO2007095644A2 (en) 2007-08-23
JP2009527740A (ja) 2009-07-30
US20100184099A1 (en) 2010-07-22
ES2354181T3 (es) 2011-03-10
AU2007214427B2 (en) 2011-11-10
CN101384901A (zh) 2009-03-11
AU2007214427A1 (en) 2007-08-23
JP5143026B2 (ja) 2013-02-13
US20070207489A1 (en) 2007-09-06
EP1984735A2 (de) 2008-10-29
CN104749378A (zh) 2015-07-01
WO2007095644A3 (en) 2007-12-27
EP1984735B1 (de) 2010-10-06
DE602007009645D1 (de) 2010-11-18
CA2642542C (en) 2012-09-25

Similar Documents

Publication Publication Date Title
DE602007009645D1 (de) Reagenzien und verfahren für krebsprognose und pathologische einstufung
DE602006002809D1 (de) Verfahren zur erkennung eines ovarialkarzinoms
EP2047262A4 (de) Verfahren zur krebsprognose auf der basis subzellulärer lokalisierung von biomarkern
EP1897940A4 (de) Zusammensetzung und verfahren zur diagnose von speiseröhrenkrebs sowie der metastasierung von speiseröhrenkrebs
EP1969363A4 (de) Verfahren und markerkombinationen zum screening auf eine veranlagung zu lungenkrebs
ATE535805T1 (de) Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen
WO2008154098A3 (en) Reagents and methods for mirna expression analysis and identification of cancer biomarkers
DE112006001755A5 (de) EU/TB-Chelat-basiertes fluoreszenzspektroskopisches Verfahren zum Nachweis von Analyten
EP1991701A4 (de) Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von krebs
DK2211180T3 (da) Anvendelse af protein SATB2 som markør til at skelne colorectal cancer fra andre former for cancer
ATE410524T1 (de) Verfahren und nukleinsäuren für die analyse von zellulären proliferationsstörungen
TWI317811B (de)
WO2013057581A8 (en) Composite biomarker for non-invasive screening, diagnosis and prognosis of colorectal cancer
EP1599603A4 (de) Diagnose- und prognoseverfahren von pankreaskrebs
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
ATE557276T1 (de) Spezifisches verfahren zum krebsnachweis
ATE408839T1 (de) Tumor marker für urothelialen krebs
WO2010009074A3 (en) Method for predicting and detecting tumor metastasis
WO2007082073A8 (en) Biomarkers for oral tongue cancer metastasis and extracapsular spread (ecs)
WO2009085196A8 (en) Methods and compositions for correlating genetic markers with prostate cancer risk
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
ATE433158T1 (de) System und verfahren zur erkennung der breite eines datenbusses
WO2013062261A3 (en) Newly identified colon cancer marker and diagnostic kit using the same
WO2008104985A3 (en) Methods for distingushing between lung squamous carcinoma and other non smallcell lung cancers
DE60317606D1 (de) Marker für Brustkrebsprognose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties